Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SUNG HO LEE

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1841426780
CMS profile
38559
Location
NYACK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$3,261.56

139 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,056.57 136
Education $204.99 3

By paying entity

PY2025 · entire year · sorted by reported total

Page 3 of 3; records 101–139 of 139 matching records. This page contains 39 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SUNG HO LEE

NPI 1841426780 · CMS profile ID 38559

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

NYACK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–139 of 139 matching records. This page contains 39 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1841426780?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SUNG HO LEE, NPI 1841426780, CMS profile ID 38559. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–139 of 139 matching records. This page contains 39 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1841426780?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). SUNG HO LEE, NPI 1841426780, CMS profile ID 38559. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–139 of 139 matching records. This page contains 39 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1841426780?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
SUNG HO LEE, NPI 1841426780, CMS profile ID 38559, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–139 of 139 matching records. This page contains 39 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1841426780?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

139 matching records · $3,261.56 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 139 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–139 of 139.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
BeOne Medicines USA, Inc. $19.6804/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202885864 CMS
Novartis Pharmaceuticals Corporation $7.0604/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200601869 CMS
PFIZER INC. $27.5904/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228960226 CMS
JAZZ PHARMACEUTICALS INC. $29.5904/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234322997 CMS
PFIZER INC. $8.9604/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228839394 CMS
Acrotech Biopharma Inc. $24.0903/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1237535934 CMS
Janssen Biotech, Inc. $30.0003/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175443696 CMS
Merck Sharp & Dohme LLC $27.9003/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238194452 CMS
ABBVIE INC. $24.4103/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202284385 CMS
Eisai Inc. $21.3103/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244514786 CMS
Novartis Pharmaceuticals Corporation $7.7603/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200601867 CMS
E.R. Squibb & Sons, L.L.C. $27.1703/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184952764 CMS
GlaxoSmithKline, LLC. $33.4503/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191681247 CMS
ARRAY BIOPHARMA INC $19.6703/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231521973 CMS
Merck Sharp & Dohme LLC $15.2803/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238058099 CMS
PUMA BIOTECHNOLOGY, INC. $20.4602/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251741740 CMS
Celgene Corporation $22.2402/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184952762 CMS
Novartis Pharmaceuticals Corporation $10.7302/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200601851 CMS
Novartis Pharmaceuticals Corporation $5.6002/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200601861 CMS
Novartis Pharmaceuticals Corporation $0.8002/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200601863 CMS
Novartis Pharmaceuticals Corporation $0.2902/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200601865 CMS
ABBVIE INC. $19.3502/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202284383 CMS
Ipsen Biopharmaceuticals, Inc $27.2402/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208836443 CMS
PFIZER INC. $29.4702/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231235999 CMS
GENZYME CORPORATION $23.8302/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233471506 CMS
Tempus AI, Inc $14.6402/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250348110 CMS
Merck Sharp & Dohme LLC $18.6202/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238090769 CMS
Janssen Biotech, Inc. $40.9102/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175443732 CMS
Janssen Biotech, Inc. $22.8801/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175443630 CMS
Ipsen Biopharmaceuticals, Inc $29.2701/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208836441 CMS
Novartis Pharmaceuticals Corporation $6.4701/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200601853 CMS
Myriad Genetic Laboratories, Inc. $18.0301/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1245407058 CMS
ABBVIE INC. $22.6601/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202284381 CMS
Merck Sharp & Dohme LLC $23.4901/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238284991 CMS
SHIELD THERAPEUTICS INC $19.7401/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249602046 CMS
Janssen Biotech, Inc. $22.3901/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175443653 CMS
Novartis Pharmaceuticals Corporation $25.7501/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200601849 CMS
Immunocore Limited $30.0001/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235824758 CMS
Alexion Pharmaceuticals, Inc. $33.3301/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202951640 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,822.55 148
PY2020 $1,526.71 77
PY2021 $627.58 14
PY2022 $592.61 24
PY2023 $795.14 36
PY2024 $1,287.87 55
PY2025 $3,261.56 139

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $473,710.65 38
PY2024 Principal investigator $173,263.79 36
PY2023 Principal investigator $194,402.29 8
PY2022 Principal investigator $47,169.73 9
PY2021 Principal investigator $39,471.60 11
PY2020 Principal investigator $150,414.56 52
PY2019 Principal investigator $133,109.16 17

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

38 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $100,617.44 12/31/2025 Non-covered Recipient Entity
Hematology Oncology Associates of Rockland
An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician s Choice in Participants with HR,HER2-Unresectable Locally Advanced or Metastatic Breast Cancer No dispute reported 06/30/2026 1232923592
Principal investigator 1 PFIZER INC. $9,786.00 12/30/2025 Non-covered Recipient Entity
Hematology Oncology Associates of Rockland
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228746485
Principal investigator 1 Janssen Research & Development, LLC $1,389.00 12/15/2025 Non-covered Recipient Entity
HIGHLAND MEDICAL PC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175311588
Principal investigator 1 Janssen Research & Development, LLC $70.00 12/01/2025 Non-covered Recipient Entity
Hematlgy Oncology Associates Of Rockland
Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia A Multi Center Randomized Double blind Placebo controlled Study No dispute reported 06/30/2026 1175253284
Principal investigator 1 PFIZER INC. $19,628.80 11/24/2025 Non-covered Recipient Entity
Hematology Oncology Associates of Rockland
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228715741
Principal investigator 1 PFIZER INC. $208.00 11/24/2025 Non-covered Recipient Entity
Hematology Oncology Associates of Rockland
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228715829
Principal investigator 1 PFIZER INC. $82.08 11/24/2025 Non-covered Recipient Entity
Hematology Oncology Associates of Rockland
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228715909
Principal investigator 1 PFIZER INC. $768.00 11/24/2025 Non-covered Recipient Entity
Hematology Oncology Associates of Rockland
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENTNAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228716083
Principal investigator 1 PFIZER INC. $19,908.70 11/19/2025 Non-covered Recipient Entity
Hematology Oncology Associates of Rockland
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228715743
Principal investigator 1 PFIZER INC. $2,987.04 11/19/2025 Non-covered Recipient Entity
Hematology Oncology Associates of Rockland
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228715745
Principal investigator 1 PFIZER INC. $461.25 11/19/2025 Non-covered Recipient Entity
Hematology Oncology Associates of Rockland
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228715905
Principal investigator 1 PFIZER INC. $23,590.88 11/19/2025 Non-covered Recipient Entity
Hematology Oncology Associates of Rockland
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228715907
Principal investigator 1 PFIZER INC. $356.50 11/19/2025 Non-covered Recipient Entity
Hematology Oncology Associates of Rockland
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228716085
Principal investigator 1 Janssen Research & Development, LLC $1,373.00 11/07/2025 Non-covered Recipient Entity
HIGHLAND MEDICAL PC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175311595
Principal investigator 1 PFIZER INC. $425.00 11/02/2025 Non-covered Recipient Entity
HEMONC OF ROCKLAND
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228728043
Principal investigator 1 PFIZER INC. $10,965.52 11/02/2025 Non-covered Recipient Entity
HEMONC OF ROCKLAND
AN INTERVENTIONAL PHASE 3 DOUBLEBLIND RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228728713
Principal investigator 1 Janssen Research & Development, LLC $70.00 11/01/2025 Non-covered Recipient Entity
Hematlgy Oncology Associates Of Rockland
Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia A Multi Center Randomized Double blind Placebo controlled Study No dispute reported 06/30/2026 1175253263
Principal investigator 1 Janssen Research & Development, LLC $70.00 10/01/2025 Non-covered Recipient Entity
Hematlgy Oncology Associates Of Rockland
Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia A Multi Center Randomized Double blind Placebo controlled Study No dispute reported 06/30/2026 1175253255
Principal investigator 1 Janssen Research & Development, LLC $70.00 09/01/2025 Non-covered Recipient Entity
Hematlgy Oncology Associates Of Rockland
Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia A Multi Center Randomized Double blind Placebo controlled Study No dispute reported 06/30/2026 1175253311
Principal investigator 1 Janssen Research & Development, LLC $1,289.00 09/01/2025 Non-covered Recipient Entity
HIGHLAND MEDICAL PC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175311604
Principal investigator 1 Janssen Research & Development, LLC $70.00 08/01/2025 Non-covered Recipient Entity
Hematlgy Oncology Associates Of Rockland
Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia A Multi Center Randomized Double blind Placebo controlled Study No dispute reported 06/30/2026 1175253319
Principal investigator 1 Janssen Research & Development, LLC $285.00 07/28/2025 Non-covered Recipient Entity
HIGHLAND MEDICAL PC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175311567
Principal investigator 1 Janssen Research & Development, LLC $57.00 07/28/2025 Non-covered Recipient Entity
HIGHLAND MEDICAL PC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175311628
Principal investigator 1 Janssen Research & Development, LLC $175.00 07/28/2025 Non-covered Recipient Entity
HIGHLAND MEDICAL PC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175311634
Principal investigator 1 Janssen Research & Development, LLC $70.00 07/01/2025 Non-covered Recipient Entity
Hematlgy Oncology Associates Of Rockland
Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia A Multi Center Randomized Double blind Placebo controlled Study No dispute reported 06/30/2026 1175253300
Principal investigator 1 Janssen Research & Development, LLC $70.00 06/01/2025 Non-covered Recipient Entity
Hematlgy Oncology Associates Of Rockland
Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia A Multi Center Randomized Double blind Placebo controlled Study No dispute reported 06/30/2026 1175253238
Principal investigator 1 Janssen Research & Development, LLC $1,389.00 05/26/2025 Non-covered Recipient Entity
HIGHLAND MEDICAL PC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175311572
Principal investigator 1 Janssen Research & Development, LLC $70.00 05/01/2025 Non-covered Recipient Entity
Hematlgy Oncology Associates Of Rockland
Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia A Multi Center Randomized Double blind Placebo controlled Study No dispute reported 06/30/2026 1175253231
Principal investigator 1 Epizyme, Inc. $1,456.13 04/30/2025 Non-covered Recipient Entity
Highland Medical, Pc
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184282309
Principal investigator 1 Janssen Research & Development, LLC $70.00 04/01/2025 Non-covered Recipient Entity
Hematlgy Oncology Associates Of Rockland
Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia A Multi Center Randomized Double blind Placebo controlled Study No dispute reported 06/30/2026 1175253246
Principal investigator 1 Janssen Research & Development, LLC $5,618.00 03/31/2025 Non-covered Recipient Entity
HIGHLAND MEDICAL PC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175311619
Principal investigator 1 Janssen Research & Development, LLC $29,425.00 03/14/2025 Non-covered Recipient Entity
HIGHLAND MEDICAL PC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175311581
Principal investigator 1 Janssen Research & Development, LLC $1,534.00 03/10/2025 Non-covered Recipient Entity
HIGHLAND MEDICAL PC
Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1175311613
Principal investigator 1 Janssen Research & Development, LLC $70.00 03/01/2025 Non-covered Recipient Entity
Hematlgy Oncology Associates Of Rockland
Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia A Multi Center Randomized Double blind Placebo controlled Study No dispute reported 06/30/2026 1175253276
Principal investigator 1 Janssen Research & Development, LLC $70.00 02/01/2025 Non-covered Recipient Entity
Hematlgy Oncology Associates Of Rockland
Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia A Multi Center Randomized Double blind Placebo controlled Study No dispute reported 06/30/2026 1175253290
Principal investigator 1 Novartis Pharmaceuticals Corporation $17,067.00 01/09/2025 Non-covered Recipient Entity
HEMATOLOGY ONCOLOGY ASSOCIATION OF ROCKLAND
A Phase III, Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (VAYHIT1) No dispute reported 06/30/2026 1190313231
Principal investigator 1 Novartis Pharmaceuticals Corporation $222,028.31 01/09/2025 Non-covered Recipient Entity
HEMATOLOGY ONCOLOGY ASSOCIATION OF ROCKLAND
A Phase 3 Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to Eltrombopag in Patients With Primary Immune Thrombocytopenia (ITP) Who Had an Insufficient Response or Relapsed After First Line Steroid Treatment (VAYHIT2) No dispute reported 06/30/2026 1190313233
Principal investigator 1 Janssen Research & Development, LLC $70.00 01/01/2025 Non-covered Recipient Entity
Hematlgy Oncology Associates Of Rockland
Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia A Multi Center Randomized Double blind Placebo controlled Study No dispute reported 06/30/2026 1175253271